Sugi Predict

Sugi Predict / Compounds / SCHEMBL1752147

SCHEMBL1752147

SCHEMBL1752147

CNc1nc(-c2ccc(F)cc2)c(C(=O)OC)c(C(C)C)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GCGR P47871 3/20 0.56
▸ LMNA P02545 3/20 0.47
▸ DHODH Q02127 1/20 0.44
▸ ADORA1 P30542 1/20 0.42
▸ SCN9A Q15858 1/20 0.42
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ CASP3 P42574 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ SENP8 Q96LD8 1/20 0.40
▸ SENP7 Q9BQF6 1/20 0.40
▸ SENP6 Q9GZR1 1/20 0.40
▸ AKT1 P31749 1/20 0.38
▸ MAPK13 O15264 1/20 0.38
▸ ALOX5 P09917 1/20 0.38
▸ MAPK12 P53778 1/20 0.38
▸ MAPK11 Q15759 1/20 0.38
▸ MAPK14 Q16539 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2211 0.88 ALDH1A1 (0.47) GCGRLMNANPC1RAB9ASMN1; SMN2
SCHEMBL28300700 0.87 ADORA1 (0.47) GCGRDHODHADORA1SCN9A
SCHEMBL28302219 0.86 ADORA1 (0.46) GCGRDHODHADORA1SCN9A
SCHEMBL22785824 0.86 GCGR (0.52) GCGRLMNADHODHSCN9ANPC1
SCHEMBL30716573 0.85 GCGR (0.58) GCGRLMNADHODHSCN9ANPC1
SCHEMBL14282780 0.85 GCGR (0.58) GCGRLMNADHODHNPC1RAB9A
SCHEMBL1751791 0.85 GCGR (0.58) GCGRLMNADHODHSCN9ANPC1
SCHEMBL1752471 0.84 GCGR (0.57) GCGRLMNADHODHADORA1NPC1
SCHEMBL30414624 0.84 GCGR (0.57) GCGRLMNADHODHSCN9ANPC1
SCHEMBL1751492 0.84 GCGR (0.57) GCGRLMNADHODHSCN9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109796414-B Method for continuously preparing rosuvastatin intermediate by adopting micro-channel modular reaction device 中国药科大学 2022-05-20 — — CN disclosed
CN-109796414-A A method of continuously preparing Rosuvastatin intermediate using microchannel module reaction unit 中国药科大学 2019-05-24 — — CN disclosed
US-8614320-B2 Preparation of aminopyrimidine compounds ASTRAZENECA UK LIMITED (GB) 2013-12-24 — — US disclosed
US-20120277432-A1 Preparation of Aminopyrimidine Compounds ASTRAZENECA UK LTD. (GB) 2012-11-01 — — US disclosed
US-8222412-B2 Preparation of aminopyrimidine compounds ASTRAZENECA UK LIMITED (GB) 2012-07-17 — — US disclosed
US-20110160455-A1 Preparation of Aminopyrimidine Compounds ASTRAZENECA UK LTD. (GB) 2011-06-30 — — US disclosed
US-7816528-B2 Preparation of aminopyrimidine compounds ASTRAZENECA UK LIMITED (GB) 2010-10-19 — — US disclosed
US-20090082380-A1 DEUTERIUM-ENRICHED ROSUVASTATIN PROTIA, LLC (US) 2009-03-26 — — US disclosed
US-20090082380-A1 DEUTERIUM-ENRICHED ROSUVASTATIN PROTIA, LLC (US) 2009-03-26 — — US disclosed
US-20080058520-A1 Preparation of Aminopyrimidine Compounds MATSUSHITA AKIO 2008-03-06 — — US disclosed
WO-2007074391-A2 PREPARATION OF A KEY INTERMEDIATE IN THE SYNTHESIS OF ROSUVASTATIN KHAMAR BAKULESH MAFATLAL (IN) 2007-07-05 — — WO disclosed
CN-1301977-C Process for preparing aminopyrimidine compounds ASTRA ZENECA BRITISH CO LTD (GB) 2007-02-28 — — CN disclosed
EP-1417180-B1 PREPARATION OF AMINOPYRIMIDINE COMPOUNDS ASTRAZENECA UK LTD (GB) 2006-12-27 — — EP disclosed
CN-1763016-A Preparation of aminopyrimidine compounds. ASTRAZENECA UK LTD (GB) 2006-04-26 — — CN disclosed
WO-2004103977-A2 PROCESS FOR THE PREPARATION OF PYRIMIDINE DERIVATIVES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2004-12-02 — — WO disclosed
EP-1417180-A4 PREPARATION OF AMINOPYRIMIDINE COMPOUNDS ASTRAZENECA UK LTD (GB) 2004-10-27 — — EP disclosed
US-20040176401-A1 Preparation of aminopyrimidine compounds ASTRAZENECA UK LIMITED (GB) 2004-09-09 — — US disclosed
CN-1527821-A Process for preparing aminopyrimidine compounds — 2004-09-08 — — CN disclosed
EP-1417180-A1 PREPARATION OF AMINOPYRIMIDINE COMPOUNDS Astrazeneca UK Limited (GB) 2004-05-12 — — EP disclosed
WO-2003006439-A1 PREPARATION OF AMINOPYRIMIDINE COMPOUNDS ASTRAZENECA UK LIMITED (GB) 2003-01-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160455-A1 Preparation of Aminopyrimidine Compounds DPYD, UMPS, IDH3B GCGR 3740/4885LMNA 4126/4885DHODH 192/4885
US-20090082380-A1 DEUTERIUM-ENRICHED ROSUVASTATIN PCSK9, HMGCR, REN GCGR 796/4885LMNA 1426/4885DHODH 163/4885
US-20040176401-A1 Preparation of aminopyrimidine compounds DPYD, IDH3B, UMPS GCGR 3928/4885LMNA 4017/4885DHODH 229/4885
US-20080058520-A1 Preparation of Aminopyrimidine Compounds DPYD, UMPS, IDH3B GCGR 3740/4885LMNA 4126/4885DHODH 192/4885
US-20120277432-A1 Preparation of Aminopyrimidine Compounds DPYD, UMPS, IDH3B GCGR 3740/4885LMNA 4126/4885DHODH 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.